Biological measurement can now scale
Computing scaled with transistors. Imaging scaled with pixels. Telecommunications scaled with bandwidth. Biological measurement did not scale.
Instead, it fragmented into modality-specific systems—PCR, ELISA, sequencing—each constrained by tradeoffs between sensitivity, speed, multiplexing, cost, and deployment.
These are not biological limits. They are architectural constraints.
Guanine introduces a new scaling model: biological information is encoded, amplified, and resolved within a programmable signal architecture.
Measurement capability expands without increasing system complexity.
Biological measurement can scale across dimensions
Guanine introduces signal density as the scaling mechanism. Each analyte is converted into a dense, encoded electrical signal—measured and resolved through software rather than hardware expansion.
Legacy systems scale by adding hardware. Guanine scales by increasing signal density.
This enables combinations that existing systems cannot achieve: high multiplex with low cost, high sensitivity with rapid turnaround, multi-analyte measurement from a single sample, and functional time-series measurement within a single test.
Not an incremental improvement—a transition from fixed diagnostic systems to programmable measurement infrastructure.
Explore the architecture
Measurement becomes programmable
Guanine replaces fixed optical systems and assay-specific hardware with a programmable electrochemical sensing architecture.
The platform is built on a patent-granted synthetic quadruplex oligonucleotide nanomaterial that enables dense, reversible signal encoding at scale. This material foundation is what allows biological information to be amplified, encoded, and measured within a single architecture. Instead of generating a single signal per binding event, each analyte is converted into a dense, encoded electrical signal, measured and resolved through software.
Each analyte becomes a programmable signal.
This is the first biological measurement system where scaling is defined in software.
A different signal model
Signal amplification is physical, not enzymatic. Multiplexing is encoded, not spatially separated. Measurement is electrical, not optical.
Signal density defines capability
System performance is determined by tags per analyte, encoding states per signal, and electrodes per system—creating a large addressable signal space inside a compact device.
Integrated measurement workflow
Sample concentration, enrichment, tagging, signal generation, and electrochemical readout are integrated within a single cartridge-based workflow.
Time becomes a measurement dimension
Stable, reversible signals enable dynamic tracking of viability, treatment response, and functional biology within a single test.
Traditional diagnostics are defined by hardware. Guanine is defined by its signal architecture.
Go deeper on the technologySepsis is a timing problem that existing systems cannot solve
Sepsis is one of the leading causes of death and the most expensive condition treated in hospitals.
Treatment decisions must be made within 1–2 hours. The gold standard—culture and susceptibility testing—requires 3–5 days.
Antibiotics are started empirically, treatment is often incorrect or delayed, and the consequences are measurable: 2–4 additional ICU days, 4–7 additional hospital days, $10k–$40k increased cost per patient, and higher mortality from delayed appropriate therapy.
The limitation is not biological. It is the inability to measure what matters within the required timeframe.
No existing approach delivers the full decision stack in the clinical window. PCR provides partial pathogen identification but not functional response. Culture provides susceptibility but is too slow. Host markers are indirect rather than causative.
No existing system can deliver identity, resistance, and functional response within the clinical decision window.
Guanine aligns measurement with decision timing by integrating genotype, phenotype, and host response within a single test.
Instead of predicting susceptibility from genetic markers alone, Guanine measures actual biological response under treatment—viability under antibiotic exposure, response across concentrations, and dynamic change over time.
Treatment is guided by observed response—not inferred risk.
Identity, resistance, and response—measured together, in time to act.
See the sepsis workflow
Host response and early stratification.
Pathogen and resistance identification.
Phenotypic susceptibility within the decision window.
From hardware-constrained assays to programmable measurement
Biological measurement today is fragmented across hardware systems—each tied to a specific modality, workflow, and infrastructure.
To launch a new assay, OEMs must either build new instrumentation or constrain the assay to an existing system. Both limit speed, capability, and market reach.
Diagnostic innovation has been gated by hardware.
Guanine provides a shared sensing architecture where assays are defined in signal—not instrumentation. Measurement is defined by signal encoding, multiplexing is defined in software, and workflows are integrated within a cartridge.
Assay development no longer requires hardware development.
This is the first biological measurement platform where new assays scale without new hardware.
A platform, not a product
New assays deploy without rebuilding systems, multiple analyte types run on a shared architecture, and capability expands without increasing system complexity.
A different development and revenue model
Decoupling assay from hardware compresses time to market, lowers capital requirements, and supports recurring cartridge revenue with software-enabled upgrades.
From instruments to infrastructure
Like cloud computing decoupled software from infrastructure, Guanine decouples biological assays from hardware.
Because the architecture is compact and low-cost, it can support point-of-care clinical settings, distributed diagnostic networks, industrial monitoring, and high-throughput precision medicine workflows on the same underlying signal architecture.
Explore the OEM platform
The conditions for a new measurement architecture now exist
Biological measurement long lacked a scaling mechanism—not because it was unnecessary, but because it was not technically achievable.
That has changed. Electrochemical sensing is now stable, low-cost, and scalable. Synthetic oligonucleotides are programmable and manufacturable at scale. Signal control and encoding now support precise, repeatable measurement.
Individually, these technologies have existed. Only recently can they be integrated into a unified measurement architecture.
Demand has outpaced existing systems
Clinical decisions increasingly require real-time results, decentralized workflows, multi-analyte measurement, and machine-readable biological data.
Architecture, not iteration
This is a transition from modality-specific instruments and sequential workflows to unified systems with software-defined capability.
Signal density provides the mechanism. Programmable architectures provide the system.
The question is no longer whether biological measurement will become programmable—
but which architecture will define it.